Cited 39 times in
Risk of diabetes in patients treated with HMG-CoA reductase inhibitors
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 왕혜진 | - |
dc.contributor.author | 윤유정 | - |
dc.contributor.author | 강은석 | - |
dc.contributor.author | 서지원 | - |
dc.contributor.author | 안철우 | - |
dc.contributor.author | 이용호 | - |
dc.contributor.author | 이현철 | - |
dc.contributor.author | 조용인 | - |
dc.contributor.author | 차봉수 | - |
dc.contributor.author | 최연정 | - |
dc.contributor.author | 최은영 | - |
dc.date.accessioned | 2016-02-04T11:01:34Z | - |
dc.date.available | 2016-02-04T11:01:34Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 0026-0495 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/139498 | - |
dc.description.abstract | OBJECTIVE: 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) are used to control blood cholesterol levels and reduce cardiovascular disease. It has been repeatedly reported that statins may cause new-onset diabetes mellitus (DM). However, limited evidence exists from direct head to head comparisons of statins on whether the risk of DM differs among statins. We investigated the risk of development of new-onset diabetes in subjects treated with different statins. METHODS: We retrospectively enrolled consecutive 3680 patients without DM or impaired fasting glucose who started receiving statin treatment for cholesterol control. We evaluated the incidence of new-onset diabetes according to the type of statin. RESULTS: The mean duration of follow-up was 62.6±15.3 months. The incidence of DM was significantly higher in the pitavastatin group (49 of 628; 7.8%) compared to that in the other statin groups [atorvastatin (68 of 1327; 5.1%), rosuvastatin (77 of 1191; 6.5%), simvastatin (11 of 326; 3.4%), and pravastatin (12 of 298; 5.8%); p=0.041]. The risk of diabetes was the highest in the pitavastatin group compared with that in the simvastatin group [hazard ratio (HR)=2.68, p=0.011]. Other statins showed no significant risk differences compared to that for simvastatin. Fasting blood glucose (FBG) level at baseline and body-mass index (BMI) were associated with the development of diabetes [FBG, HR=1.11, p<0.001; BMI, HR=1.02, p=0.005]. CONCLUSIONS: Among the five statins, pitavastatin showed the strongest effect on the development of new-onset diabetes. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 282~288 | - |
dc.relation.isPartOf | METABOLISM-CLINICAL AND EXPERIMENTAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Atorvastatin Calcium | - |
dc.subject.MESH | Diabetes Mellitus/epidemiology* | - |
dc.subject.MESH | Diabetes Mellitus/etiology* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorobenzenes/therapeutic use | - |
dc.subject.MESH | Heptanoic Acids/therapeutic use | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use* | - |
dc.subject.MESH | Hypercholesterolemia/complications | - |
dc.subject.MESH | Hypercholesterolemia/drug therapy* | - |
dc.subject.MESH | Hypercholesterolemia/epidemiology* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Pravastatin/therapeutic use | - |
dc.subject.MESH | Pyrimidines/therapeutic use | - |
dc.subject.MESH | Pyrroles/therapeutic use | - |
dc.subject.MESH | Quinolines/therapeutic use | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Risk Factors | - |
dc.subject.MESH | Rosuvastatin Calcium | - |
dc.subject.MESH | Simvastatin/therapeutic use | - |
dc.subject.MESH | Sulfonamides/therapeutic use | - |
dc.title | Risk of diabetes in patients treated with HMG-CoA reductase inhibitors | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Yongin Cho | - |
dc.contributor.googleauthor | EunYeong Choe | - |
dc.contributor.googleauthor | Yong-ho Lee | - |
dc.contributor.googleauthor | Ji Won Seo | - |
dc.contributor.googleauthor | Younjeong Choi | - |
dc.contributor.googleauthor | Yujung Yun | - |
dc.contributor.googleauthor | Hye Jin Wang | - |
dc.contributor.googleauthor | Chul Woo Ahn | - |
dc.contributor.googleauthor | Bong Soo Cha | - |
dc.contributor.googleauthor | Hyun Chul Lee | - |
dc.contributor.googleauthor | Eun Seok Kang | - |
dc.identifier.doi | 10.1016/j.metabol.2014.09.008 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A02422 | - |
dc.contributor.localId | A02586 | - |
dc.contributor.localId | A00068 | - |
dc.contributor.localId | A02270 | - |
dc.contributor.localId | A02989 | - |
dc.contributor.localId | A03301 | - |
dc.contributor.localId | A03866 | - |
dc.contributor.localId | A03996 | - |
dc.contributor.localId | A04108 | - |
dc.contributor.localId | A04153 | - |
dc.contributor.localId | A01913 | - |
dc.relation.journalcode | J02223 | - |
dc.identifier.eissn | 1532-8600 | - |
dc.identifier.pmid | 25312577 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S002604951400290X | - |
dc.subject.keyword | Diabetes mellitus | - |
dc.subject.keyword | HMG CoA reductase inhibitors | - |
dc.subject.keyword | Hypercholesterolemia | - |
dc.subject.keyword | Statin | - |
dc.contributor.alternativeName | Wang, Hye Jin | - |
dc.contributor.alternativeName | Yun, Yu Jung | - |
dc.contributor.alternativeName | Kang, Eun Seok | - |
dc.contributor.alternativeName | Seo, Ji Won | - |
dc.contributor.alternativeName | Ahn, Chul Woo | - |
dc.contributor.alternativeName | Lee, Yong Ho | - |
dc.contributor.alternativeName | Lee, Hyun Chul | - |
dc.contributor.alternativeName | Cho, Yong In | - |
dc.contributor.alternativeName | Cha, Bong Soo | - |
dc.contributor.alternativeName | Choi, Youn Jeong | - |
dc.contributor.alternativeName | Choe, Eun Yeong | - |
dc.contributor.affiliatedAuthor | Wang, Hye Jin | - |
dc.contributor.affiliatedAuthor | Yun, Yu Jung | - |
dc.contributor.affiliatedAuthor | Kang, Eun Seok | - |
dc.contributor.affiliatedAuthor | Ahn, Chul Woo | - |
dc.contributor.affiliatedAuthor | Lee, Yong Ho | - |
dc.contributor.affiliatedAuthor | Lee, Hyun Chul | - |
dc.contributor.affiliatedAuthor | Cho, Yong In | - |
dc.contributor.affiliatedAuthor | Cha, Bong Soo | - |
dc.contributor.affiliatedAuthor | Choi, Youn Jeong | - |
dc.contributor.affiliatedAuthor | Choe, Eun Yeong | - |
dc.contributor.affiliatedAuthor | Seo, Ji Won | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 64 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 282 | - |
dc.citation.endPage | 288 | - |
dc.identifier.bibliographicCitation | METABOLISM-CLINICAL AND EXPERIMENTAL, Vol.64(4) : 282-288, 2015 | - |
dc.identifier.rimsid | 55433 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.